Spa Industry Association

JULY 29, 2024

Online support and tools to successfully market iconic Get Ready Wrap® focus on increasing revenues and guest satisfaction. Palm Desert, Calif (July 16, 2024) Beauty business expert Lori Crete is pleased to introduce the new SpaStar® Pro Portal with resources and tools to support spa owners, spa directors, and estheticians. The portal includes brand elements, sales scripts, shelf-talkers, video demonstrations, and articles on best practices, aimed at successfully marketing SpaStar’s iconic Get R

Sales 98

Sales Tools Marketing Branding 98

Beauty Launchpad

JULY 29, 2024

Two major influencers in the world of salon management have joined forces to elevate the in-salon experience with a new $28,000 color bar makeover up for grabs.

Salon Management 98

Salon Management Salon Management 98

Spa Industry Association

JULY 29, 2024

LAKE BUENA VISTA, FL – July 18, 2024 – The Salt Therapy Association (STA) is thrilled to announce that Myndstream, a leading health and wellness music provider, will bring the highly talented Peter Kater , a multi-Grammy award-winning and multi-Platinum-selling pianist, composer, producer, and breathwork practitioner, as a featured speaker to STAconLIVE 2024.

Therapy 98

Therapy 98

The Dermatology Digest

JULY 29, 2024

Benjamin Ungar, MD, the Director of the Alopecia Center of Excellence at Mount Sinai in New York City, discusses what the U.S. Food and Drug Administration approval of Sun Pharma’s LEQSELVI (deuruxolitinib) will mean for adults with severe alopecia areata. The post What Will the FDA Approval of Sun Pharma’s Alopecia Drug Mean for Patients? appeared first on The Dermatology Digest.

Dermatology 73

Dermatology 73

MedEsthetics

JULY 29, 2024

Have recent aesthetic treatment innovations led to increased patient demand for body sculpting?

Innovations 78

Innovations Treatments 78

Dermatology Times

JULY 29, 2024

Explore how BCs are supported through complex drug approvals and ensuring patients have access to prescribed medications.

Dermatology 74

Dermatology Medical 74

Dermatology Times

JULY 29, 2024

Researchers reported gender differences among individuals with skin conditions and compared sociodemographic, clinical and psychological variables.

Clinic 45

Clinic 45

Aesthetic Advancements Institute (AAI)

JULY 29, 2024

Chances are, if you’re an active injector on social media, you’ve heard of the neurotoxins Lip Flip trend. While it’s actually been around for a long time, it provides a great opportunity for marketing to your patients who are just now hearing about it! What is a lip flip? A lip flip with neurotoxins is a subtle, but transformative procedure that enhances lip appearance without the need for dermal fillers.

Social Media 36

Social Media Injections Marketing Safety 36

Dermatology Times

JULY 29, 2024

Researchers conducted an assessment of the Nationwide Emergency Department Sample to analyze frequency of visits attributed to young patients with DEB.

Hospital 41

Hospital 41

The Dermatology Digest

JULY 29, 2024

Enrollment in Phase 3 VALOR study evaluating brepocitinib in dermatomyositis is now complete, according to Priovant Therapeutics. Data are anticipated in the second half of calendar year 2025, with a potential New Drug Application (NDA) submission to follow. Brepocitinib is a dual selective inhibitor of oral tyrosine kinase 2 (TYK2) inhibitor and J anus kinase (JAK1) administered orally once daily.

Hospital 36

Hospital Therapy Dermatology Medical 36

Dermatology Times

JULY 29, 2024

From ER visits for dystrophic epidermolysis bullosa to rates of axillary hyperhidrosis, catch up on top pediatric insights from July.

Dermatology 41

Dermatology 41

The Dermatology Digest

JULY 29, 2024

Alumis Inc. is initiating the Onward Phase 3 Clinical Program evaluating ESK-001, an oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. This Phase 3 program consists of two identical 24-week global Phase 3 clinical trials (ONWARD1 and ONWARD2) designed to evaluate the efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis and includes a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of respo

Clinic 36

Clinic Safety Office Treatments 36

Dermatology Times

JULY 29, 2024

Researchers noted how historical bias in dermatology research has impacted the understanding and treatment of conditions in darker skin.

Dermatology 41

Dermatology Treatments 41

Dermatology Times

JULY 29, 2024

Approved down to the age of 6, the treatment is covered by 2 pharmacy benefit manager contracts to provide timely coverage.

Dermatitis 41

Dermatitis Management Treatments 41